Form 4: Crinetics Pharmaceuticals CEO Sells 10,000 Shares Under 10b5-1 Plan

Crinetics Pharmaceuticals CEO Richard Scott Struthers sold 10,000 shares of common stock at an average price of $57.57 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Richard Scott Struthers, the President and CEO of Crinetics Pharmaceuticals, sold 10,000 shares of common stock on December 2, 2024.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan.
• The shares were sold at a weighted average price of $57.57 per share, with individual sales ranging from $56.90 to $58.07.
• Following the transaction, Mr. Struthers directly owns 257,485 shares and indirectly owns 791,805 shares through family trusts and a spouse.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing for an insider stock sale under a pre-arranged plan, which is neither positive nor negative.

Industry Context

This is a routine filing for insider transactions and is common for executives who have pre-arranged trading plans.

Comparison to Industry Standards

• Sales under 10b5-1 plans are a common practice among executives at publicly traded companies to avoid accusations of insider trading.
• The reported sale is within the typical range of executive transactions and does not appear to be unusual compared to similar filings from other biotech companies.

Stakeholder Impact

• The sale may have a minor impact on the stock price, but it is unlikely to be significant given the pre-arranged nature of the transaction.

Key Dates

Keywords

Crinetics Pharmaceuticals, Richard Scott Struthers, insider trading, Form 4, 10b5-1 plan, stock sale, executive transaction